See more : Kesselrun Resources Ltd. (KES.V) Income Statement Analysis – Financial Results
Complete financial analysis of BELLUS Health Inc. (BLU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BELLUS Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jiangxi Sunshine Dairy Co., Ltd. (001318.SZ) Income Statement Analysis – Financial Results
- First Citizens Bancshares, Inc. (FIZN) Income Statement Analysis – Financial Results
- Zhejiang Changsheng Sliding Bearings Co., Ltd. (300718.SZ) Income Statement Analysis – Financial Results
- Kewaunee Scientific Corporation (KEQU) Income Statement Analysis – Financial Results
- Cepton, Inc. (CPTN) Income Statement Analysis – Financial Results
BELLUS Health Inc. (BLU)
About BELLUS Health Inc.
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00K | 16.00K | 15.00K | 26.79K | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.12M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.74M | 2.91M | 109.80K | 0.00 | 2.25M | 5.52M | 118.83K |
| Cost of Revenue | 3.51B | 2.22B | 1.43B | 994.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -137.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 693.62K | -470.29K | 0.00 | 0.00 | -1.16M | 0.00 | 0.00 |
| Gross Profit | -3.51B | -2.22B | -1.43B | -994.49M | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.26M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.05M | 3.38M | 109.80K | 0.00 | 3.41M | 5.52M | 118.83K |
| Gross Profit Ratio | -21,967,104.08% | -13,887,173.94% | -9,536,119.55% | -3,711,740.75% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 106.48% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.71% | 116.14% | 100.00% | 0.00% | 151.65% | 100.00% | 100.00% |
| Research & Development | 58.89M | 59.79M | 23.73M | 20.00M | 5.28M | 2.87M | 1.13M | 931.76K | 1.46M | 1.19M | 998.16K | 1.29M | 7.05M | 10.04M | 23.60M | 55.45M | 49.54M | 40.61M | 24.42M | 5.71M | 8.03M | 6.56M | 3.19M |
| General & Administrative | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 0.00 | 7.69M | 8.57M | 11.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 611.90K | 3.71M | 6.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 3.47M | 8.30M | 12.28M | 18.45M | 15.17M | 14.67M | 23.25M | 18.29M | 5.75M | 2.44M | 396.43K | 1.02M |
| Other Expenses | -491.00K | -754.00K | -507.00K | -543.53K | -479.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 653.38K | 5.34M | -5.05M | 13.11M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 65.73M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
| Cost & Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 66.42M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
| Interest Income | 5.08M | 233.00K | 1.05M | 1.16M | 265.78K | 63.62K | 74.40K | 104.49K | 170.56K | 189.71K | 137.71K | 105.78K | 151.98K | 102.00K | 907.00K | 0.00 | 2.36M | 2.08M | 0.00 | 520.42K | 1.14M | 0.00 | 0.00 |
| Interest Expense | 78.00K | 55.00K | 39.00K | 22.97K | 3.67K | 8.75K | 8.18K | 7.93K | 89.59K | 133.36K | 220.14K | 333.01K | 526.92K | 324.00K | 271.00K | 0.00 | 151.45K | 461.68K | 0.00 | 46.37K | 232.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.12M | 426.00K | 1.22M | 1.28M | 325.25K | 63.62K | 49.10K | 104.49K | 345.43K | 658.36K | -17.49M | 45.05K | 1.47M | 693.00K | 1.88M | 399.00K | 335.82K | 2.60M | 1.70M | 497.67K | 585.56K | 278.82K | 224.15K |
| EBITDA | -72.76M | -72.86M | -31.72M | -24.82M | -6.95M | -4.46M | -1.51M | 28.10K | -1.78M | -2.43M | -21.12M | -1.71M | -13.22M | -7.21M | -46.07M | -66.97M | -62.16M | -60.94M | -42.60M | -11.46M | -8.22M | -1.44M | -4.09M |
| EBITDA Ratio | -454,768.75% | -455,362.50% | -211,453.33% | -92,637.22% | -27,038.13% | -3,396.99% | -107.29% | 0.97% | -87.04% | -114.72% | -914.36% | -56.95% | -549.21% | 6,215.52% | -7,888.36% | -4,443.66% | -2,266.69% | -2,091.58% | -38,800.14% | 0.00% | -365.10% | -26.07% | -3,440.36% |
| Operating Income | -77.88M | -73.28M | -32.94M | -26.10M | -7.27M | -4.52M | -1.56M | -76.39K | -2.13M | -3.09M | -3.64M | -1.76M | -14.69M | -21.12M | -45.66M | -68.66M | -63.68M | -63.69M | -44.30M | -11.95M | -8.81M | -1.72M | -4.31M |
| Operating Income Ratio | -486,768.75% | -458,025.00% | -219,613.33% | -97,431.66% | -28,303.89% | -3,445.47% | -110.78% | -2.63% | -103.91% | -145.79% | -157.40% | -58.45% | -610.09% | 18,204.31% | -7,817.64% | -4,555.81% | -2,321.87% | -2,185.81% | -40,350.15% | 0.00% | -391.10% | -31.13% | -3,629.00% |
| Total Other Income/Expenses | 1.86M | 1.86M | 1.19M | -280.19K | 603.51K | 3.08M | -86.30K | 348.78K | 389.37K | 2.18M | -9.60M | 5.34M | -5.05M | 12.89M | -2.57M | -12.42M | -999.45K | 1.38M | 714.67K | -1.35M | 74.51K | 0.00 | 316.65K |
| Income Before Tax | -76.02M | -71.42M | -31.76M | -26.39M | -6.67M | -1.44M | -1.65M | 272.40K | -1.74M | -911.93K | -13.24M | 3.58M | -19.73M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -13.30M | -8.73M | 0.00 | -4.00M |
| Income Before Tax Ratio | -475,125.00% | -446,393.75% | -211,713.33% | -98,477.40% | -25,955.23% | -1,098.79% | -116.90% | 9.39% | -84.89% | -43.04% | -573.11% | 119.24% | -819.68% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -387.79% | 0.00% | -3,362.52% |
| Income Tax Expense | 60.00K | -199.00K | 39.00K | 22.97K | -607.18K | 48.51K | 11.16K | -19.46K | -42.21K | -617.97K | 18.44M | 227.23K | 374.94K | 13.44M | 1.32M | -1.94M | -1.50M | -2.04M | -626.83K | -365.56K | 152.98K | 58.14K | -227.53K |
| Net Income | -76.08M | -71.22M | -31.80M | -26.41M | -6.06M | -1.49M | -1.61M | 145.57K | -1.66M | -818.96K | -13.32M | 3.35M | -20.11M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -12.93M | -8.89M | -1.78M | -3.77M |
| Net Income Ratio | -475,500.00% | -445,150.00% | -211,973.33% | -98,563.12% | -23,592.29% | -1,135.76% | -114.05% | 5.02% | -81.27% | -38.65% | -576.81% | 111.68% | -835.26% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -394.58% | -32.18% | -3,171.04% |
| EPS | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | 1.38 | -10.28 | -6.34 | -105.15 | -198.86 | -181.01 | -196.26 | -156.38 | -52.10 | -53.29 | -11.00 | -32.16 |
| EPS Diluted | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | -0.67 | -10.28 | -6.30 | -105.15 | -198.86 | -181.01 | -187.15 | -137.04 | -44.64 | -49.86 | -11.00 | -32.16 |
| Weighted Avg Shares Out | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 2.47M | 1.96M | 1.30M | 458.62K | 407.69K | 357.31K | 317.48K | 278.73K | 248.27K | 166.73K | 161.45K | 117.17K |
| Weighted Avg Shares Out (Dil) | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 6.04M | 1.96M | 1.31M | 458.62K | 407.69K | 357.31K | 332.93K | 318.06K | 289.73K | 178.21K | 161.45K | 117.17K |
BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights
LAVAL, Quebec--( BUSINESS WIRE )--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitivity indications, today reported its financial and operating results...
Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?
Here is how Bellus Health (BLU) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that an abstract reviewing clinical data...
Bellus: Expected Phase 3 Start Makes This A Long-Term Play
BELLUS Health intends to initiate two phase 3 studies in Q4 of 2022; these will be CALM-1 and CALM-2 studies using BLU-5937 for treatment of patients with refractory chronic cough. Final results from the phase 3 CALM-1 and CALM-2 studies...
BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three abstracts reviewing clinical data...
BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today reported its financial and operating results for...
BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offering in Canada and the United States (the “Offering”) of 16,540,541 common shares at a price to...
Why BELLUS Health Stock Fell Today
Issuing new shares will leave it with plenty of money in the bank.
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States
LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into...
BELLUS Health Shares Slide On Public Offering Of Shares In Canada And US
BELLUS Health Inc (NASDAQ: BLU) (TSX:BLU) has filed a preliminary prospectus supplement to its amended and restated short form base shelf prospectus dated December 14, 2021, amending and restating the short form base shelf prospectus dated December 23, 2020, in connection.
Source: https://incomestatements.info
Category: Stock Reports